PHILADELPHIA— The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as editor-in-chief of Clinical Cancer Research, one of eight peer-reviewed journals published by the AACR.
Flaherty is director of the Termeer Center for Targeted Therapies and director of clinical research at the Massachusetts General Hospital Cancer Center, in Boston, where he was named as the Richard Saltonstall endowed chair in oncology, and a professor of medicine at Harvard Medical School. He officially began his tenure as editor-in-chief on Jan. 1.
“I am thrilled to take on this role at a time when the opportunities to advance science through methodologically rigorous clinical investigation are at an all-time high,” Flaherty said. “I benefit greatly from having served under Dr. Ken Anderson’s visionary leadership of the journal for the past six years as a senior editor.”
Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. Manuscripts are stringently reviewed for high standards of scientific merit; the journal accepts only those that report results of novel, timely, and broadly significant research for publication.
“Dr. Flaherty is a world-renowned physician-scientist, and the American Association for Cancer Research is delighted to welcome him to the position of editor-in-chief of this important cancer research journal,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “His expertise in clinical and translational cancer research, coupled with his substantial experience in publishing cutting-edge peer-reviewed articles in the field, will help us build on the journal’s success and enhance the exchange of knowledge among researchers in the cancer field.”
Flaherty is an active member of the AACR. He has been a senior editor of Clinical Cancer Research with oversight of the melanoma section of the journal since 2010, as well as a scientific editorial board member of Cancer Discovery since its inception.
Flaherty's research focuses on the understanding of the molecular and clinical consequences of inhibiting oncogenes and oncogenic pathways in melanoma, while establishing individual therapeutic approaches and constructing rational combinatorial therapies. A pioneer in developing targeted therapies matched to the genetic characteristics of a patient's tumor, Flaherty led early clinical trials on the development of vemurafenib and trametinib and the dabrafenib/trametinib combination.
Flaherty is also the deputy chair for biomarker sciences and the chair of the developmental therapeutics committee in the Eastern Cooperative Oncology Group, a scientific advisory committee member for the Melanoma Research Foundation, and a president of the Society for Melanoma Research.